Acrux and its partner Padagis announced the launch of an AB-rated generic version of Emla® Cream in the United States. Emla® (prilocaine 2.5% and lidocaine 2.5%) Cream is indicated as a topical anaesthetic for use on: normal intact skin for local analgesia; and genital mucous membranes for superficial minor surgery and as pre-treatment for infiltration anaesthesia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.081 AUD | +3.85% | +19.12% | +84.09% |
Apr. 03 | Acrux, TruPharma Launch Dapsone 5% Gel in US | MT |
Feb. 29 | Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+84.09% | 15.64M | |
+15.91% | 41.97B | |
+22.40% | 22.34B | |
+18.48% | 15.25B | |
+16.12% | 14B | |
+45.12% | 12.06B | |
-9.58% | 6.8B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.18% | 5.49B |
- Stock Market
- Equities
- ACR Stock
- News Acrux Limited
- Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States